Publications by authors named "Matthijs Versteegh"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

833

Total Likes

137

Extended Reach

361,704

Social Features

33
E
Effectiveness of Seizure Dogs for People With Severe Refractory Epilepsy: Results From the EPISODE Study.
Valérie van Hezik-Wester, Saskia de Groot, Tim Kanters, Louis Wagner, Jacqueline Ardesch, Werner Brouwer, Isaac Corro Ramos, Saskia le Cessie, Matthijs Versteegh, Job van Exel

Neurology· March 2024

Videos about Article: user user

2 31 2 16

View All Article and Social Media Activity
C
Cost-Utility Analysis of Treatment Sequences for Moderate-to-Severe Crohn's Disease.
Matthijs M Versteegh, Simone A Huygens, Inigo Bermejo, Sabine Grimm, Marieke Pierik

Pharmacoeconomics· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exit strategies in patients with stable MS: Cost-effectiveness of extended interval dosing of ocrelizumab and natalizumab versus de-escalating to cladribine.
Matthijs M Versteegh, Simone A Huygens

Mult Scler Relat Disord· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparative Efficacy of all Available Pharmaceutical Therapies for Moderate to Severe Crohn's Disease: A Systematic Review and Network Meta-Analysis.
Matthijs Versteegh, Demy L Idema, Simone Huygens, Kevin Jenniskens, Marieke Pierik

Gastro Hep Adv· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reply to comment on Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study.
Yi Hsuan Chen, Michiel Kroesen, Mischa S Hoogeman, Matthijs M Versteegh, Carin A Uyl-de Groot

Clin Transl Radiat Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[How sustainable is our oncological care?].
Femke A Van der Zant, Johanna W M Aarts, Schelto Kruijff, Hanneke Van Laarhoven, Matthijs Versteegh

Ned Tijdschr Geneeskd· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment-related toxicity, utility and patient-reported outcomes of head and neck cancer patients treated with proton therapy: A longitudinal study.
Yi Hsuan Chen, Michiel Kroesen, Mischa Hoogeman, Matthijs Versteegh, Carin Uyl-de Groot

Clin Transl Radiat Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Cost-Effectiveness of Seizure Dogs for Persons Living With Severe Refractory Epilepsy: Results From the EPISODE Study.
Valérie van Hezik-Wester, Saskia de Groot, Tim Kanters, Louis Wagner, Jacqueline Ardesch, Matthijs Versteegh

Value Health· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of early highly effective versus escalation treatment strategies in relapsing multiple sclerosis estimated using a treatment-sequence model.
Ide Smets, Matthijs Versteegh, Simone Huygens, Beatrijs Wokke, Joost Smolders

Mult Scler· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefits of sphingosine-1-phosphate receptor modulators in relapsing MS estimated with a treatment sequence model.
Cato E A Corsten, Simone A Huygens, Matthijs M Versteegh, Beatrijs H A Wokke, Ide Smets

Mult Scler Relat Disord· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Societal Utilities for Cognitive Impairment in Schizophrenia: Developing a Preference-Based Scoring Algorithm Based on the Schizophrenia Cognition Rating Scale.
Irene Santi, Andrew J Lloyd, Claudia E Hastedt, Matthijs M Versteegh

Adv Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health-economic benefits of anti-CD20 treatments in relapsing multiple sclerosis estimated using a treatment-sequence model.
Ide Smets, Matthijs Versteegh, Simone Huygens, Cato Corsten, Beatrijs Wokke

Mult Scler J Exp Transl Clin· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact and transferability of cost-effectiveness of testing in metastatic breast cancer in three health systems.
Rositsa Koleva-Kolarova, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten-van Mölken

Per Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Financial incentives to promote personalized medicine in Europe: an overview and guidance for implementation.
Rositsa Koleva-Kolarova, László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Balázs Nagy, Matthijs Versteegh

Per Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of extended testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK.
Rositsa Koleva-Kolarova, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, Maureen Rutten-van Mölken

Per Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness and budget impact analysis of screening strategies for maturity-onset diabetes of the young in three European countries.
László Szilberhorn, Tamás Zelei, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh

Per Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of genetic-based screening strategies for maturity-onset diabetes of the young.
Gábor Kovács, Dávid Nagy, László Szilberhorn, Tamás Zelei, Zsolt Gaál, Matthijs Versteegh

Per Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lessons learned from the application of the HEcoPerMed guidance to three modeling case studies.
Balázs Nagy, Tamás Zelei, Heleen Vellekoop, Simone Huygens, Matthijs Versteegh

Per Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HEcoPerMed, personalized medicine from a health economic perspective: lessons learned and potential opportunities ahead.
Maureen Rutten-van Mölken, Matthijs Versteegh, Balázs Nagy, Sarah Wordsworth

Per Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of alternative testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries.
Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, László Szilberhorn, Tamás Zelei

Per Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice.
Bram Wouterse, Pieter van Baal, Matthijs Versteegh, Werner Brouwer

Pharmacoeconomics· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[The qaly: informing decision-making in health care].
Matthijs Versteegh, Marcel Dijkgraaf

Ned Tijdschr Geneeskd· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-Effectiveness Analysis of Treating Patients With NTRK-Positive Cancer With the Histology-Independent Therapy Entrectinib.
Simone Huygens, Heleen Vellekoop, Matthijs Versteegh, Irene Santi, László Szilberhorn

Value Health· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In search of a 'pan-European value set'; application for EQ-5D-3L.
Ayesha Sajjad, Matthijs M Versteegh, Irene Santi, Jan Busschbach, Judit Simon

BMC Med Res Methodol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of illness in people with medically refractory epilepsy who suffer from daily to weekly seizures: 12-month follow-up of participants in the EPISODE study.
Valérie van Hezik-Wester, Saskia de Groot, Tim Kanters, Matthijs Versteegh, Louis Wagner

Front Neurol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis